<DOC>
	<DOCNO>NCT00770939</DOCNO>
	<brief_summary>Diabetic foot ulcer challenge health care professional effective topical therapeutic intervention . Growth factor treatment show beneficial healing diabetic foot ulcer conjunction extensive surgical debridement . Autologues platelet releasate contains platelet derive growth factor appear effective standard therapy case study . This protocol evaluate heal effect Vivostat PRF treatment non-eschemic foot ulcer identify responder enable sample size calculation subsequent pivotal trial .</brief_summary>
	<brief_title>Evaluation Effect Vivostat Platelet Rich Fibrin ( PRF ) Treatment Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>At least 4 week history ( wound area measurement ) within wound care institution first visit ( week 3 ) . In case referral patient history must document All patient must complete 3 week screen period i.e . interview access first meeting . During 3 week period patient compliance monitor . Age &gt; 18 year Type I Type II Diabetes Mellitus Ulcer ankle present least 4 week , receive best practice care Ulcer area 0,5 16 cm2 If one ulcer bilateral ulcer , investigator shall choose one index ulcer treat ( typically large one ) . The ulcer receive standard care include study Ulcer type : University Texas grade IA . Evidence adequate arterial perfusion : Toe pressure read ≥ 30 mmHg toe miss , transcutaneous oxygen ( TcPO2 ) ≥ 30mmHg foot . Patient foot appropriately load ( contact cast , pneumatic walk cast ) Orthopaedic assessment complete rule mechanical source ulceration Relative wound area reduction le 50 % week 3 week 0 ( prescreening period ) Signed informed consent Clear indication surgery ( vascular reconstruction skin transplant ) Ulcer expose bone tendon Bone involvement ( probe bone xray ) Patients 3 ulcer foot investigate Osteomyelitis Clinical sign infection Necrosis wound ( one week screen period ) . Patients know MRSA Malnutrition . Albumin &lt; 2,5g/dl Ulcers result electrical , chemical , radiation burn HbA1c &gt; 12 % Male : Hb &lt; 8 mmol/l ( 12,9 g/dlFemale : Hb &lt; 7 mmol/l ( 11,3 g/dl ) Platelet count &lt; 140 *109/l Pregnancy fertile woman practice sufficient birth control Fertile woman positive pregnancy test week 0 Lactating woman Patients haemodialysis History peripheral vascular repair within 4 week prior study enrollment Bleeding disorder , haemophilia , sickle cell disease , thrombocytopenia , leukaemia blood dyscrasias Current treatment malignancy neoplastic disease collagen vascular disease Highly communicable disease disease may limit follow ( e.g . immunocompromised condition , hepatitis , active tuberculosis ) Patient inadequate venous access draw blood History alcohol drug abuse within last year prior randomization Patient know psychological , developmental , physical , emotional social disorder ailment may interfere study requirement Patients enrol clinical trial wound treatment within 30 day prior enrollment Noncompliance screening period Patients receive growth factor therapy e.g . becaplermin within 7 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Complete heal chronic diabetic foot ulcer</keyword>
	<keyword>Platelet Rich Fibrin</keyword>
	<keyword>Vivostat</keyword>
	<keyword>Growth factor treatment</keyword>
	<keyword>Treatment chronic diabetic foot ulcer</keyword>
</DOC>